India’s Stand Against Data Exclusivity: Safeguarding the ‘Pharmacy of the World’

In recent trade negotiations, the Government of India has maintained a firm stance against the inclusion of 'data exclusivity' (DE) provisions. Data exclusivity is a form of legal protection that prevents generic drug manufacturers from using the clinical trial data of an innovator drug to gain regulatory approval for a specific period. By rejecting these clauses, India aims to prevent delays in the market entry of affordable generic versions of life-saving medicines.

Currently, generic manufacturers in India can gain regulatory approval by proving 'bio-equivalence' to the original drug without repeating expensive and time-consuming clinical trials. If DE were implemented, generic companies would be forced to either wait for the exclusivity period to expire (often 5-10 years) or conduct their own clinical trials. The government argues that repeating such trials is not only economically unviable for the generic industry but also ethically questionable, as it involves unnecessary testing on human subjects for drugs already proven safe and effective.

This move is consistent with India’s broader Intellectual Property Rights (IPR) framework, which seeks to balance the rewards for innovation with the requirements of public health. India’s Patents Act, particularly Section 3(d), already prevents 'evergreening' of patents. Data exclusivity is often viewed as a 'TRIPS-plus' measure—provisions that go beyond the requirements of the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. For a country often called the 'pharmacy of the world,' accepting DE would undermine its ability to export low-cost medicines to other developing nations, potentially triggering a global public health crisis.